Local Side Effects of Sublingual and Oral Immunotherapy

Journal of Allergy and Clinical Immunology: In Practice

Volumn 5, Issue 1, 2017, Pages 13-21

  Passalacqua, Giovanni ^a   Nowak Węgrzyn, Anna ^b   Canonica, Giorgio Walter ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse events; Food allergy; Local side effects; Oral desensitization; Oral immunotherapy; Respiratory allergy; Safety; Sublingual immunotherapy

Indexed keywords

IMMUNOLOGIC AGENT; ALLERGEN;

ABDOMINAL PAIN; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ARTICLE; CLINICAL EFFECTIVENESS; DESENSITIZATION; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD ALLERGY; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOMODULATION; NAUSEA; ORAL IMMUNOTHERAPY; PEANUT ALLERGY; RISK FACTOR; SUBLINGUAL IMMUNOTHERAPY; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VOMITING; ADVERSE DRUG REACTION; ANAPHYLAXIS; ANIMAL; CLINICAL TRIAL (TOPIC); DOSE CALCULATION; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; FOOD HYPERSENSITIVITY; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PROCEDURES; UNITED STATES;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ALLERGENS; ANAPHYLAXIS; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DOSAGE CALCULATIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EUROPEAN UNION; FOOD HYPERSENSITIVITY; HUMANS; SUBLINGUAL IMMUNOTHERAPY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84995688339     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2016.06.020     Document Type: Article

References (94)

1. 1 Canonica, G.W., Passalacqua, G., Noninjection routes for immunotherapy. J Allergy Clin Immunol 111 (2003), 437–448.
2. 2 Committee on the Safety of Medicines, CSM update: desensitizing vaccines. Br Med J, 293, 1986, 948.
3. 3 Passalacqua, G., Canonica, G.W., Allergen immunotherapy: history and future developments. Immunol Allergy Clin North Am 36 (2016), 1–12.
4. 4 Aaronson, D.W., Gandhi, T.K., Incorrect allergy injections: allergists’ experiences and recommendations for prevention. J Allergy Clin Immunol 113 (2004), 1117–1121.
5. 5 Windom, H.H., Lockey, R.F., An update on the safety of specific immunotherapy. Curr Opin Allergy Clin Immunol 8 (2008), 571–576.
6. 6 Scadding, K., Brostoff, J., Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin Allergy 16 (1986), 483–491.
7. 7 Bousquet, J., Lockey, R., Mailing, H.J., Allergen immunotherapy: therapeutical vaccines for allergic diseases. World Health Organization position paper 53:44 Suppl (1998), 1–42.
8. 8 Malling, H.J., EAACI position paper on local immunotherapy. Allergy 53 (1998), 933–944.
9. 9 Bousquet, J., Khaltaev, N., Cruz, A.A., Denburg, J., Fokkens, W.J., Togias, A., et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 63 (2008), 8–160.
10. 10 Canonica, G.W., Bousquet, J., Casale, T., Lockey, R.F., Baena-Cagnani, C.E., Pawankar, R., et al. Sub-lingual immunotherapy: World Allergy Organization position paper 2009. Allergy 64 (2009), 1–59.
11. 11 Canonica, G.W., Cox, L., Pawankar, R., Baena-Cagnani, C.E., Blaiss, M., Bonini, S., et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J, 7, 2014, 6.
12. 12 Passalacqua, G., Canonica, G.W., Sublingual immunotherapy: focus on tablets. Ann Allergy Asthma Immunol 115 (2015), 4–10.
13. 13 Albin, S., Nowak-Węgrzyn, A., Potential treatments for food allergy. Immunol Allergy Clin North Am 35 (2015), 77–100.
14. 14 Jones, S.M., Burks, A.W., Dupont, C., State of the art on food allergen immunotherapy: oral, sublingual, and epicutaneous. J Allergy Clin Immunol 133 (2014), 318–323.
15. 15 Arasi, S., Passalacqua, G., Caminiti, L., Crisafulli, G., Fiamingo, C., Pajno, G.B., Efficacy and safety of sublingual immunotherapy in children. Expert Rev Clin Immunol 12 (2016), 49–56.
16. 16 Wilson, D.R., Torres, L., Durham, S.R., Sublingual immunotherapy for allergic rhinitis. Allergy 60 (2005), 3–8.
17. 17 Calamita, Z., Saconato, H., Pelà, A.B., Atallah, A.N., Efficacy of sublingual immunotherapy in asthma: systematic review of randomized clinical trials. Allergy 61 (2006), 1162–1172.
18. 18 Penagos, M., Passalacqua, G., Compalati, E., Baena-Cagnani, C.E., Orozco, S., Pedroza, A., et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 133 (2008), 599–609.
19. 19 Penagos, M., Compalati, E., Tarantini, F., Baena-Cagnani, R., Huerta, J., Passalacqua, G., et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 97 (2006), 141–148.
20. 20 Compalati, E., Passalacqua, G., Bonini, M., Canonica, G.W., The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 64 (2009), 1570–1579.
21. 21 Di Bona, D., Plaia, A., Scafidi, V., Leto-Barone, M.S., Di Lorenzo, G., Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol 126 (2010), 558–566.
22. 22 Radulovic, S., Calderon, M., Duncan, W., Durham, S., Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev, 8, 2010, CD002893.
23. 23 Di Bona, D., Plaia, A., Leto-Barone, M.S., La Piana, S., Di Lorenzo, G., Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis: a systematic review and meta-analysis. JAMA Intern Med 175 (2015), 1301–1309.
24. 24 Calderon, M.A., Penagos, M., Sheikh, A., Canonica, G.W., Durham, S., Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database Syst Rev, 6, 2011, CD007685.
25. 25 Cox, L., Larenas-Linneman, D., Nolte, H., Weldon, D., Finegold, I., Nelson, H.S., Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 117 (2006), 1021–3515.
26. 26 Calderón, M.A., Simons, F.E., Malling, H.J., Lockey, R.F., Moingeon, P., Demoly, P., Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 67 (2012), 302–311.
27. 27 Dahl, R., Stender, A., Rak, S., Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 61 (2006), 185–190.
28. 28 Durham, S.R., Yang, W.H., Pedersen, M.R., Johansen, N., Rak, S., Sublingual immunotherapy with once-daily grass-allergen tablets: a randomised controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 117 (2006), 802–809.
29. 29 Didier, A., Malling, H.J., Worm, M., Horak, F., Jäger, S., Montagut, A., et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 120 (2007), 1338–1345.
30. 30 Ott, H., Sieber, J., Brehler, R., Fölster-Holst, R., Kapp, A., Klimek, L., et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 64 (2009), 179–186.
31. 31 Wahn, U., Tabar, A., Kuna, P., Halken, S., Montagut, A., de Beaumont, O., et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 123 (2009), 160–166.
32. 32 Bufe, A., Eberle, P., Franke-Beckmann, E., Funck, J., Kimmig, M., Klimek, L., et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 123 (2009), 167–173.
33. 33 Blaiss, M., Maloney, J., Nolte, H., Gawchik, S., Yao, R., Skoner, D.P., Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 127 (2011), 64–71.
34. 34 Nelson, H.S., Nolte, H., Creticos, P., Maloney, J., Wu, J., Bernstein, D.I., Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 127 (2011), 72–80.
35. 35 Wahn, U., Klimek, L., Ploszczuk, A., Adelt, T., Sandner, B., Trebas-Pietras, E., et al. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study. J Allergy Clin Immunol 130 (2012), 886–893.
36. 36 Cox, L.S., Casale, T.B., Nayak, A.S., Bernstein, D.I., Creticos, P.S., Ambroisine, L., et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol 130 (2012), 1327–1334.
37. 37 de Bot, C.M., Moed, H., Berger, M.Y., Röder, E., Hop, W.C., de Groot, H., et al. Sublingual immunotherapy not effective in house dust mite-allergic children in primary care. Pediatr Allergy Immunol 23 (2012), 150–158.
38. 38 Nolte, H., Hébert, J., Berman, G., Gawchik, S., White, M., Kaur, A., et al. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. Ann Allergy Asthma Immunol 110 (2013), 450–456.
39. 39 Creticos, P.S., Maloney, J., Bernstein, D.I., Casale, T., Kaur, A., Fisher, R., et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol 131 (2013), 1342–1349.
40. 40 Bergmann, K.C., Demoly, P., Worm, M., Fokkens, W.J., Carrillo, T., Tabar, A.I., et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol 133 (2014), 1608–1614.
41. 41 Creticos, P.S., Esch, R.E., Couroux, P., Gentile, D., D'Angelo, P., Whitlow, B., et al. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol 133 (2014), 751–758.
42. 42 Mosbech, H., Deckelmann, R., de Blay, F., Pastorello, E.A., Trebas-Pietras, E., Andres, L.P., et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 134 (2014), 568–575.
43. 43 Maloney, J., Bernstein, D.I., Nelson, H., Creticos, P., Hébert, J., Noonan, M., et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol 112 (2014), 146–153.
44. 44 Wang, L., Yin, J., Fadel, R., Montagut, A., de Beaumont, O., Devillier, P., House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. Allergy 69 (2014), 1181–1188.
45. 45 Okamoto, Y., Okubo, K., Yonekura, S., Hashiguchi, K., Goto, M., Otsuka, T., et al. Efficacy and safety of sublingual immunotherapy for two seasons in patients with Japanese cedar pollinosis. Int Arch Allergy Immunol 166 (2015), 177–188.
46. 46 Ibanez, R., Kaiser, F., Knecht, R., Armentia, A., Schöpfer, H., Tholstrup, B., et al. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr Allergy Immunol 18 (2007), 516–522.
47. 47 Didier, A., Worm, M., Horak, F., Sussman, G., de Beaumont, O., Le Gall, M., et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 128 (2011), 559–566.
48. 48 Di Rienzo, V., Pagani, A., Parmiani, S., Passalacqua, G., Canonica, G.W., Post-marketing surveillance study on the safety of sublingual immunotherapy in children. Allergy 54 (1999), 1110–1113.
49. 49 Lombardi, C., Gargioni, S., Melchiorre, A., Passalacqua, G., Safety of sublingual immunotherapy in adults: a post marketing surveillance study. Allergy 56 (2001), 889–892.
50. 50 Pajno, G.B., Peroni, D.G., Vita, D., Pietrobelli, A., Parmiani, S., Boner, A.L., Safety of sublingual immunotherapy in children with asthma. Paediatr Drugs 5 (2003), 777–781.
51. 51 Fiocchi, A., Pajno, G., La Grutta, S., Pezzuto, F., Incorvaia, C., Sensi, L., et al. Safety of SLIT in children aged 3 to 7 years. Ann Allergy Asthma Immunol 95 (2005), 254–258.
52. 52 Agostinis, F., Tellarini, L., Falagiani, P., Canonica, G.W., Passalacqua, G., Safety of SLIT in very young children. Allergy, 60, 2005, 133.
53. 53 Di Rienzo, V., Minelli, M., Musarra, A., Sambugaro, R., Pecora, S., Canonica, W.G., et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 35 (2005), 560–564.
54. 54 Rodríguez-Pérez, N., Ambriz-Moreno Mde, J., Canonica, G.W., Penagos, M., Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Ann Allergy Asthma Immunol 101 (2008), 304–310.
55. 55 Agostinis, F., Foglia, C., Landi, M., Cottini, M., Lombardi, C., Canonica, G.W., et al. The safety of sublingual immunotherapy with one or multiple pollen allergens in children. Allergy 63 (2008), 1637–1639.
56. 56 Lombardi, C., Gargioni, S., Cottini, M., Canonica, G.W., Passalacqua, G., The safety of sublingual immunotherapy with one or more allergens in adults. Allergy 63 (2008), 375–376.
57. 57 Passalacqua, G., Baena-Cagnani, C.E., Bousquet, J., Canonica, G.W., Casale, T.B., Cox, L., et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol 132 (2013), 93–98.
58. 58 MedDRA Medical Dictionary for Regulatory Activities. Maintenance Support Services and Organization. Available from: http://www.meddramsso.com/. Accessed January 27, 2016.
59. 59 Brown, E.G., Wood, L., Wood, S., The medical dictionary for regulatory activities (MedDRA). Drug Saf 20 (1999), 109–117.
60. 60 Bousquet, C., Lagier, G., Lillo-Le Louet, A., Le Beller, C., Venot, A., Jaulent, M.C., Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions. Drug Saf 28 (2005), 19–34.
61. 61 Cox, L., Larenas-Linnemann, D., Lockey, R.F., Passalacqua, G., Speaking the same language: the World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol 125 (2010), 569–574.
62. 62 Pitsios, C., Demoly, P., Bilò, M.B., Gerth van Wijk, R., Pfaar, O., Sturm, G.J., et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy 70 (2015), 897–909.
63. 63 Sampson, H.A., Aceves, S., Bock, S.A., James, J., Jones, S., Lang, D., et al. Food allergy: a practice parameter update-2014. J Allergy Clin Immunol 134 (2014), 1016–1025.
64. 64 Oppenheimer, J.J., Nelson, H.S., Bock, S.A., Christensen, F., Leung, D.Y., Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 90 (1992), 256–262.
65. 65 Nelson, H.S., Lahr, J., Rule, R., Bock, A., Leung, D., Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 99 (1997), 744–751.
66. 66 Enrique, E., Pineda, F., Malek, T., Bartra, J., Basagana, M., Tella, R., et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract 2. J Allergy Clin Immunol 116 (2005), 1073–1079.
67. 67 Keet, C.A., Frischmeyer-Guerrerio, P.A., Thyagarajan, A., Schroeder, J.T., Hamilton, R.G., Boden, S., et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol 129 (2012), 448–555.
68. 68 Fernandez-Rivas, M., Garrido, F.S., Nadal, J.A., Diaz, dDMD., Garcia, B.E., Gonzalez-Mancebo, E., et al. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy 64 (2009), 876–883.
69. 69 Kim, E.H., Bird, J.A., Kulis, M., Laubach, S., Pons, L., Shreffler, W.G., et al. Sublingual immunotherapy for peanut allergy: clinical and immunological evidence of desensitization. J Allergy Clin Immunol 127 (2011), 640–646.
70. 70 Fleischer, D.M., Burks, A.W., Vickery, B.P., Scurlock, A.M., Wood, R.A., Jones, S.M., et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol 131 (2013), 119–127.
71. 71 Burks, A.W., Wood, R.A., Jones, S.M., Sicherer, S.H., Fleischer, D.M., Scurlock, A.M., et al. Sublingual immunotherapy for peanut allergy: long-term follow-up of a randomized multicenter trial. J Allergy Clin Immunol 135 (2015), 1240–1248.
72. 72 Narisety, S.D., Frischmeyer-Guerrerio, P.A., Keet, C.A., Gorelik, M., Schroeder, J., Hamilton, R.G., et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol 135 (2015), 1275–1282.
73. 73 Varshney, P., Jones, S.M., Scurlock, A.M., Perry, T.T., Kemper, A., Steele, P., et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 127 (2011), 654–660.
74. 74 Jones, S.M., Pons, L., Roberts, J.L., Scurlock, A.M., Perry, T.T., Kulis, M., et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 124 (2009), 292–300.
75. 75 Anagnostou, K., Islam, S., King, Y., Foley, L., Pasea, L., Bond, S., et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet 383 (2014), 1297–1304.
76. 76 Skripak, J.M., Nash, S.D., Rowley, H., Brereton, N.H., Oh, S., Hamilton, R.G., et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol 122 (2008), 1154–1160.
77. 77 Longo, G., Barbi, E., Berti, I., Meneghetti, R., Pittalis, A., Ronfani, L., et al. Specific oral tolerance induction in children with very severe cow's milk-induced reactions. J Allergy Clin Immunol 121 (2008), 343–347.
78. 78 Pajno, G.B., Caminiti, L., Ruggeri, P., De Luca, R., Vita, D., La Rosa, M., et al. Oral immunotherapy for cow's milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study. Ann Allergy Asthma Immunol 105 (2010), 376–381.
79. 79 Sato, S., Utsunomiya, T., Imai, T., Yanagida, N., Asaumi, T., Ogura, K., et al. Wheat oral immunotherapy for wheat-induced anaphylaxis. J Allergy Clin Immunol 136 (2015), 1131–1133.
80. 80 Rodriguez del Rio, P., Diaz-Perales, A., Sanchez-Garcia, S., Escudero, C., do Santos, P., Catarino, M., et al. Oral immunotherapy in children with IgE-mediated wheat allergy: outcome and molecular changes. J Investig Allergol Clin Immunol 4 (2014), 240–248.
81. 81 Blumchen, K., Ulbricht, H., Staden, U., Dobberstein, K., Beschorner, J., de Oliveira, L.C., et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol 126 (2010), 83–91.
82. 82 Burks, A.W., Jones, S.M., Wood, R.A., Fleischer, D.M., Sicherer, S.H., Lindblad, R.W., et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med 367 (2012), 233–243.
83. 83 Pajno, G., Landi, M., Passalacqua, G., Oral immunotherapy for cow's milk allergy. Curr Opin Allergy Clin Immunol 12 (2012), 271–277.
84. 84 Lucendo, A.J., Arias, A., Tenias, J.M., Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 113 (2014), 624–629.
85. 85 Narisety, S.D., Skripak, J.M., Steele, P., Hamilton, R.G., Matsui, E.C., Burks, A.W., et al. Open-label maintenance after milk oral immunotherapy for IgE-mediated cow's milk allergy. J Allergy Clin Immunol 124 (2009), 610–612.
86. 86 Varshney, P., Steele, P.H., Vickery, B.P., Bird, J.A., Thyagarajan, A., Scurlock, A.M., et al. Adverse reactions during peanut oral immunotherapy home dosing. J Allergy Clin Immunol 124 (2009), 1351–1352.
87. 87 Nadeau, K.C., Kohli, A., Iyengar, S., DeKruyff, R.H., Umetsu, D.T., Oral immunotherapy and anti-IgE antibody-adjunctive treatment for food allergy. Immunol Allergy Clin North Am 32 (2012), 111–133.
88. 88 Nadeau, K.C., Schneider, L.C., Hoyte, L., Borras, I., Umetsu, D.T., Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. J Allergy Clin Immunol 127 (2011), 1622–1624.
89. 89 Schneider, L.C., Rachid, R., LeBovidge, J., Blood, E., Mittal, M., Umetsu, D.T., A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol 132 (2013), 1368–1374.
90. 90 Wood, R.A., Kim, J.S., Lindblad, R., Nadeau, K., Henning, A.K., Dawson, P., et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy. J Allergy Clin Immunol 137 (2016), 1103–1110.
91. 91 Begin, P., Dominguez, T., Wilson, S.P., Bacal, L., Mehrotra, A., Kausch, B., et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using omalizumab. Allergy Asthma Clin Immunol, 10, 2014, 7.
92. 92 Pajno, G.B., Caminiti, L., Salzano, G., Crisafulli, G., Aversa, T., Messina, M.F., et al. Comparison between two maintenance feeding regimens after successful cow's milk oral desensitization. Pediatr Allergy Immunol 24 (2013), 376–381.
93. 93 Jutel, M., Agache, I., Bonini, S., Burks, A.W., Calderon, M., Canonica, W., et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol 136 (2015), 556–568.
94. 94 Wasserman, R.L., Factor, J.M., Baker, J.W., Mansfield, L.E., Katz, Y., Hague, A.R., et al. Oral immunotherapy for peanut allergy: multipractice experience with epinephrine-treated reactions. J Allergy Clin Immunol Pract 2 (2014), 91–96.